Entera Bio Ltd. (ENTX) Research

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

Market snapshot

Symbol
ENTX
Price
$1.21
Day change
+0.83%
Market cap
$59.6M
P/E ratio
-4.67x
52-week range
0.91-3.22
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Recent news

  • Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'— PLTR, RZLV, ENTX In Focus (UPDATED)

    Editor's Note: The future prices of benchmark tracking ETFs and the headline were updated in the story. U.S. stock futures rose on Monday following Friday's sharp sell-off. Futures of the major benchmark indices were higher after they entered the correction territory last week, falling more than 10% below their 52-week highs.

  • Stock Market Today: S&P 500, Dow Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'—Palantir, Rezolve AI, Entera Bio In Focus

    U.S. stock futures rose on Monday following Friday's sharp sell-off. Futures of the major benchmark indices were higher after they entered the correction territory last week, falling more than 10% below their 52-week highs.

Peer companies

  • Acumen Pharmaceuticals, Inc. (ABOS)
  • Agenus Inc. (AGEN)
  • Anixa Biosciences, Inc. (ANIX)
  • TuHURA Biosciences, Inc. (HURA)
  • Inovio Pharmaceuticals, Inc. (INO)
  • Opus Genetics, Inc. (IRD)
  • Seres Therapeutics, Inc. (MCRB)
  • Seer, Inc. (SEER)

Recent insider activity

  • Galitzer Hillel — A-Award (72993 shares) on 2026-05-07
  • Yaacov-Garbeli Dana — A-Award (58394 shares) on 2026-05-07
  • Burshtein Gregory — A-Award (87591 shares) on 2026-05-07
  • Germano Geno J — P-Purchase (20000 shares) on 2026-03-09
  • Ellis Sean — P-Purchase (10000 shares) on 2026-03-05

Open Entera Bio Ltd. (ENTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.